Radiopharm Theranostics (ASX:RAD) and AtomVie Global Radiopharma partnered with Radiopharm Ventures to develop and manufacture the 177Lu-BetaBart radio-antibody for treating solid tumors, according to a Wednesday filing with the Australian Securities Exchange.
The first-in-human therapeutic trial with 177Lu-BetaBart is set to start in the US in 2025, the filing said.
Radiopharm Ventures is a joint venture between Radiopharm Theranostics and MD Anderson Cancer Center in Texas, according to the filing.
Shares of Radiopharm Theranostics rose nearly 4% in midday trade.
Price (AUD): $0.03, Change: $+0.0010, Percent Change: +3.85%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.